Tabelecleucel
Epstein-Barr Virus-Associated Lymphoproliferative Disorder
Pierre Fabre MedicamentCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Epstein-Barr Virus-Associated Lymphoproliferative Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valganciclovir Viracta Therapeutics, Inc. | Phase 2 | B |
Retrovir University of Miami | Phase 2 | CCC |
Methotrexate University of Miami | Phase 2 | CCC |
Hydroxyurea University of Miami | Phase 2 | CCC |
Arginine Butyrate HemaQuest Pharmaceuticals Inc. | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Tabelecleucel is also rated in:
disease related to hematopoietic stem cell transplantActive
BB
Indicative · Phase 3
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →